Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
4 studies found for:    INCB050465 | lymphoma OR CLL | INCB050465
Show Display Options
Rank Status Study
1 Recruiting A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Condition: Diffuse Large B-cell Lymphoma
Intervention: Drug: INCB050465
2 Not yet recruiting A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Conditions: Relapsed Marginal Zone Lymphoma;   Refractory Marginal Zone Lymphoma
Intervention: Drug: INCB050465
3 Not yet recruiting An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Condition: Follicular Lymphoma
Interventions: Drug: INCB050465;   Drug: Idelalisib
4 Recruiting Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Condition: Relapsed or Refractory Follicular Lymphoma
Interventions: Drug: INCB050465;   Drug: Hexal;   Drug: Gazyvaro

Study has passed its completion date and status has not been verified in more than two years.